Recent advances in identification of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) have helped diagnosis, classification, and treatment prediction of different IIM subtypes [11,12,13]. Here, MAPKAPK5-AS1 is linked to myositis disease.